- April 8, 2026CAMBRIDGE, Mass., April 8, 2026—Anumana, Inc., a leader in cardiovascular AI, today announced U.S. Food and Drug Administration (FDA) clearance…
- March 28, 2026CAMBRIDGE, Mass. – March 28, 2026 – Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA)…
- March 24, 2026Recognition highlights Anumana’s leadership in AI-driven cardiovascular detection and clinical decision support CAMBRIDGE, Mass., March 24, 2026—Anumana, a leader in…
- March 16, 2026Cardiology, in particular, offers a clear view into why so many AI solutions struggle to scale and what differentiates those…
- February 1, 2026Anumana was founded in 2021 as the culmination of a joint effort between the Mayo Clinic and nference, an early…
- November 26, 2025As we strive to improve clinical decison making and patient outcomes – predictive analytics are a wonderful tool to help us in that goal.…
- November 10, 2025Featured science studies simultaneously published in JACC and presented at AHA 2025 looked at artificial intelligence applied to an electrocardiogram (ECG-AI) for heart failure…
- October 24, 2025The rapid growth and widespread adoption of large language models (LLMs) across real-world applications offer a host of new opportunities…
- October 1, 2025AI is transforming diagnostics by identifying subtle patterns, streamlining workflows, and accelerating time to diagnosis. This piece will explore how…
- July 25, 2025Royal Philips has launched the Philips ECG AI Marketplace, which gives cardiac care teams access to multiple vendor offerings in…
Anumana Receives First and Only FDA Clearance for ECG-AI Cardiac Amyloidosis Algorithm Using a Standard 12-Lead ECG
